PF-05280586 vs Rituximab-abbs (Truxima)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

PF-05280586

Marketed by Pfizer

Approved in Rheumatoid Arthritisbiologic (registry-typed, subtype undisclosed)
Partial signal

NCT01526057 · Phase 2 · completed

The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.

Reported efficacy

Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion); AUC 0-inf of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Rituximab-Pfizer 453 micrograms per milliliter (Standard Deviation 153) | Rituximab-EU 422 micrograms per milliliter (Standard Deviation 111) | Rituximab-US 430 micrograms per milliliter (Standard Deviation 163) (met)

Result source: NCT01526057

Rituximab-abbs (Truxima)

Marketed by Celltrion and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02149121 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.

Reported efficacy

Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)

Result source: NCT02149121

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPF-05280586Rituximab-abbs (Truxima)
ACR2077.1% vs 90%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 81.8% vs 90% wk 25 · n 33 · Phase na · primary NCT01643928
  • 73.7% vs 90% wk 25 · n 30 · Phase na · primary NCT01643928
  • 69.6% vs 77.4% wk 13 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 77.4% wk 13 · n 33 · Phase na · primary NCT01643928
  • 82.8% vs 77.4% wk 13 · n 30 · Phase na · primary NCT01643928
  • 66.7% vs 71% wk 6 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 71% wk 6 · n 33 · Phase na · primary NCT01643928
  • 76.7% vs 71% wk 6 · n 30 · Phase na · primary NCT01643928
  • 50% vs 59.4% wk 1 · n 58 · Phase na · primary NCT01643928
  • 63.6% vs 59.4% wk 1 · n 33 · Phase na · primary NCT01643928
  • 60% vs 59.4% wk 1 · n 30 · Phase na · primary NCT01643928
  • 50% vs 60.3% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 54.2% vs 62.2% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 67.6% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 50.7% vs 70.3% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 49.3% vs 60.8% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 56.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 34.2% vs 33.8% wk 3 · n 73 · Phase 2 · secondary NCT01526057
—Not reported
ACR5051.4% vs 30%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 63.6% vs 30% wk 25 · n 33 · Phase na · primary NCT01643928
  • 36.8% vs 30% wk 25 · n 30 · Phase na · primary NCT01643928
  • 37.5% vs 41.9% wk 13 · n 58 · Phase na · primary NCT01643928
  • 66.7% vs 41.9% wk 13 · n 33 · Phase na · primary NCT01643928
  • 58.6% vs 41.9% wk 13 · n 30 · Phase na · primary NCT01643928
  • 33.3% vs 51.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 51.5% vs 51.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 53.3% vs 51.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 17.2% vs 28.1% wk 1 · n 58 · Phase na · primary NCT01643928
  • 48.5% vs 28.1% wk 1 · n 33 · Phase na · primary NCT01643928
  • 30% vs 28.1% wk 1 · n 30 · Phase na · primary NCT01643928
  • 21% vs 38.1% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 27.8% vs 37.8% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 24.7% vs 36.5% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 35.6% vs 40.5% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 21.9% vs 32.4% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 16.2% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 8.2% vs 5.4% wk 3 · n 73 · Phase 2 · secondary NCT01526057
—Not reported
ACR7022.9% vs 10%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 36.4% vs 10% wk 25 · n 33 · Phase na · primary NCT01643928
  • 15.8% vs 10% wk 25 · n 30 · Phase na · primary NCT01643928
  • 23.2% vs 32.3% wk 13 · n 58 · Phase na · primary NCT01643928
  • 36.4% vs 32.3% wk 13 · n 33 · Phase na · primary NCT01643928
  • 34.5% vs 32.3% wk 13 · n 30 · Phase na · primary NCT01643928
  • 21.1% vs 22.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 33.3% vs 22.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 30% vs 22.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 5.2% vs 12.5% wk 1 · n 58 · Phase na · primary NCT01643928
  • 21.2% vs 12.5% wk 1 · n 33 · Phase na · primary NCT01643928
  • 10% vs 12.5% wk 1 · n 30 · Phase na · primary NCT01643928
  • 16.1% vs 17.5% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 13.9% vs 23% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 15.1% vs 18.9% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 28.4% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 12.3% vs 17.6% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 6.8% vs 6.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 2.7% vs 2.7% wk 3 · n 73 · Phase 2 · secondary NCT01526057
—Not reported
DAS28-CRP remission45.7% vs 20%vs Rituximab-EUwk 25 · n 58NCT01643928
11 other results
  • 27.3% vs 20% wk 25 · n 33 · Phase na · primary NCT01643928
  • 21.1% vs 20% wk 25 · n 30 · Phase na · primary NCT01643928
  • 33.9% vs 46.7% wk 13 · n 58 · Phase na · primary NCT01643928
  • 45.5% vs 46.7% wk 13 · n 33 · Phase na · primary NCT01643928
  • 37.9% vs 46.7% wk 13 · n 30 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 58 · Phase na · primary NCT01643928
  • 34.4% vs 38.7% wk 6 · n 33 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 30 · Phase na · primary NCT01643928
  • 3.9% vs 10.7% wk 1 · n 58 · Phase na · primary NCT01643928
  • 19.4% vs 10.7% wk 1 · n 33 · Phase na · primary NCT01643928
  • 7.1% vs 10.7% wk 1 · n 30 · Phase na · primary NCT01643928
—Not reported
HAQ-DI, change-0.4 vs -0.5vs Rituximabwk 25 · n 73NCT01526057
6 other results
  • -0.4 vs -0.6 wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.6 wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.6 wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.5 wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.3 wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • -0.2 vs -0.2 wk 3 · n 73 · Phase 2 · secondary NCT01526057
—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

PF-05280586
77.1% vs 90%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 81.8% vs 90% wk 25 · n 33 · Phase na · primary NCT01643928
  • 73.7% vs 90% wk 25 · n 30 · Phase na · primary NCT01643928
  • 69.6% vs 77.4% wk 13 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 77.4% wk 13 · n 33 · Phase na · primary NCT01643928
  • 82.8% vs 77.4% wk 13 · n 30 · Phase na · primary NCT01643928
  • 66.7% vs 71% wk 6 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 71% wk 6 · n 33 · Phase na · primary NCT01643928
  • 76.7% vs 71% wk 6 · n 30 · Phase na · primary NCT01643928
  • 50% vs 59.4% wk 1 · n 58 · Phase na · primary NCT01643928
  • 63.6% vs 59.4% wk 1 · n 33 · Phase na · primary NCT01643928
  • 60% vs 59.4% wk 1 · n 30 · Phase na · primary NCT01643928
  • 50% vs 60.3% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 54.2% vs 62.2% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 67.6% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 50.7% vs 70.3% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 49.3% vs 60.8% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 56.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 34.2% vs 33.8% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab-abbs (Truxima)
—Not reported

ACR50

PF-05280586
51.4% vs 30%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 63.6% vs 30% wk 25 · n 33 · Phase na · primary NCT01643928
  • 36.8% vs 30% wk 25 · n 30 · Phase na · primary NCT01643928
  • 37.5% vs 41.9% wk 13 · n 58 · Phase na · primary NCT01643928
  • 66.7% vs 41.9% wk 13 · n 33 · Phase na · primary NCT01643928
  • 58.6% vs 41.9% wk 13 · n 30 · Phase na · primary NCT01643928
  • 33.3% vs 51.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 51.5% vs 51.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 53.3% vs 51.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 17.2% vs 28.1% wk 1 · n 58 · Phase na · primary NCT01643928
  • 48.5% vs 28.1% wk 1 · n 33 · Phase na · primary NCT01643928
  • 30% vs 28.1% wk 1 · n 30 · Phase na · primary NCT01643928
  • 21% vs 38.1% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 27.8% vs 37.8% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 24.7% vs 36.5% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 35.6% vs 40.5% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 21.9% vs 32.4% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 16.2% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 8.2% vs 5.4% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab-abbs (Truxima)
—Not reported

ACR70

PF-05280586
22.9% vs 10%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 36.4% vs 10% wk 25 · n 33 · Phase na · primary NCT01643928
  • 15.8% vs 10% wk 25 · n 30 · Phase na · primary NCT01643928
  • 23.2% vs 32.3% wk 13 · n 58 · Phase na · primary NCT01643928
  • 36.4% vs 32.3% wk 13 · n 33 · Phase na · primary NCT01643928
  • 34.5% vs 32.3% wk 13 · n 30 · Phase na · primary NCT01643928
  • 21.1% vs 22.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 33.3% vs 22.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 30% vs 22.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 5.2% vs 12.5% wk 1 · n 58 · Phase na · primary NCT01643928
  • 21.2% vs 12.5% wk 1 · n 33 · Phase na · primary NCT01643928
  • 10% vs 12.5% wk 1 · n 30 · Phase na · primary NCT01643928
  • 16.1% vs 17.5% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 13.9% vs 23% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 15.1% vs 18.9% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 28.4% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 12.3% vs 17.6% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 6.8% vs 6.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 2.7% vs 2.7% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab-abbs (Truxima)
—Not reported

DAS28-CRP remission

PF-05280586
45.7% vs 20%vs Rituximab-EUwk 25 · n 58NCT01643928
11 other results
  • 27.3% vs 20% wk 25 · n 33 · Phase na · primary NCT01643928
  • 21.1% vs 20% wk 25 · n 30 · Phase na · primary NCT01643928
  • 33.9% vs 46.7% wk 13 · n 58 · Phase na · primary NCT01643928
  • 45.5% vs 46.7% wk 13 · n 33 · Phase na · primary NCT01643928
  • 37.9% vs 46.7% wk 13 · n 30 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 58 · Phase na · primary NCT01643928
  • 34.4% vs 38.7% wk 6 · n 33 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 30 · Phase na · primary NCT01643928
  • 3.9% vs 10.7% wk 1 · n 58 · Phase na · primary NCT01643928
  • 19.4% vs 10.7% wk 1 · n 33 · Phase na · primary NCT01643928
  • 7.1% vs 10.7% wk 1 · n 30 · Phase na · primary NCT01643928
Rituximab-abbs (Truxima)
—Not reported

HAQ-DI, change

PF-05280586
-0.4 vs -0.5vs Rituximabwk 25 · n 73NCT01526057
6 other results
  • -0.4 vs -0.6 wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.6 wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.6 wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.5 wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.3 wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • -0.2 vs -0.2 wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab-abbs (Truxima)
—Not reported

Modified Sharp score, change

PF-05280586
—Not reported
Rituximab-abbs (Truxima)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. PF-05280586: 5 of 5 rows · Rituximab-abbs (Truxima): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPF-05280586Rituximab-abbs (Truxima)
DAS28-CRP
absolute change · score
-1.7 vs -2 Rituximab score @ 25wka,b,c,d
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-2.7 vs -2.6 Rituxan score @ 48wka,b,c,d
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Dropout rate
12.3%e
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
17.2%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
9.1%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
13%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
4.1%e
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
0%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
1.2%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Serious AEs
6.8%e
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
6.1%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
12.9%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
13.3%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.9%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
11.1%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
8.3%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
8.1%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
3.3%CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
e
upper respiratory tract infection 9.6%
fatigue 6.8%
hypertension 5.5%
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 9 more results
rheumatoid arthritis 9.1%
vomiting 6.1%
back pain 3%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 9.7%
back pain 6.5%
sinusitis 6.5%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 10%
urinary tract infection 10%
arthralgia 6.7%
NCT01643928 · Phase na · registry result, not featured evidence
diarrhoea 6.7%
oropharyngeal pain 6.7%
gastroenteritis 3.3%
NCT01643928 · Phase na · registry result, not featured evidence
diarrhoea 6.9%
nausea 6.9%
oropharyngeal pain 6.9%
NCT01643928 · Phase na · registry result, not featured evidence
upper respiratory tract infection 10.3%
alanine aminotransferase increased 6.9%
aspartate aminotransferase increased 6.9%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 6.9%
urinary tract infection 6.9%
fatigue 5.2%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 9.3%
urinary tract infection 9.3%
bronchitis 7.4%
NCT01643928 · Phase na · registry result, not featured evidence
bronchitis 10.4%
rheumatoid arthritis 10.4%
urinary tract infection 10.4%
NCT01643928 · Phase na · registry result, not featured evidence
infusion-related reaction 20.5%
upper respiratory tract infection 14.9%
urinary tract infection 9.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
upper respiratory tract infection 8.2%
urinary tract infection 6.6%
infusion-related reaction 3.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation context differs: baseline_threshold differs (none recorded versus swollen_joint_count>=6).
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 25 weeks versus 48 weeks.
  5. ePopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

PF-05280586

ACR20 34.2% (n=73) vs 33.8% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 18 more results
54.8% (n=73) vs 56.8% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
49.3% (n=73) vs 60.8% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
50.7% (n=73) vs 70.3% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
54.8% (n=73) vs 67.6% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
54.2% (n=73) vs 62.2% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
50% (n=73) vs 60.3% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
50% (n=58) vs 59.4% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
63.6% (n=33) vs 59.4% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
60% (n=30) vs 59.4% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
66.7% (n=58) vs 71% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
84.8% (n=33) vs 71% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
76.7% (n=30) vs 71% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
69.6% (n=58) vs 77.4% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
84.8% (n=33) vs 77.4% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
82.8% (n=30) vs 77.4% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
77.1% (n=58) vs 90% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
81.8% (n=33) vs 90% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
73.7% (n=30) vs 90% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
ACR70 2.7% (n=73) vs 2.7% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 18 more results
6.8% (n=73) vs 6.8% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
12.3% (n=73) vs 17.6% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
19.2% (n=73) vs 28.4% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
15.1% (n=73) vs 18.9% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
13.9% (n=73) vs 23% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
16.1% (n=73) vs 17.5% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
5.2% (n=58) vs 12.5% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
21.2% (n=33) vs 12.5% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
10% (n=30) vs 12.5% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
21.1% (n=58) vs 22.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
33.3% (n=33) vs 22.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
30% (n=30) vs 22.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
23.2% (n=58) vs 32.3% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
36.4% (n=33) vs 32.3% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
34.5% (n=30) vs 32.3% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
22.9% (n=58) vs 10% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
36.4% (n=33) vs 10% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
15.8% (n=30) vs 10% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
ACR50 8.2% (n=73) vs 5.4% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 18 more results
19.2% (n=73) vs 16.2% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
21.9% (n=73) vs 32.4% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
35.6% (n=73) vs 40.5% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
24.7% (n=73) vs 36.5% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
27.8% (n=73) vs 37.8% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
21% (n=73) vs 38.1% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
17.2% (n=58) vs 28.1% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
48.5% (n=33) vs 28.1% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
30% (n=30) vs 28.1% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
33.3% (n=58) vs 51.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
51.5% (n=33) vs 51.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
53.3% (n=30) vs 51.6% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
37.5% (n=58) vs 41.9% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
66.7% (n=33) vs 41.9% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
58.6% (n=30) vs 41.9% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
51.4% (n=58) vs 30% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
63.6% (n=33) vs 30% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
36.8% (n=30) vs 30% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
EULAR Good 14.5% (n=73) vs 10.8% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 18 more results
22.5% (n=73) vs 22.5% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
30.9% (n=73) vs 31.5% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
41.8% (n=73) vs 44.4% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
36.4% (n=73) vs 38% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
35% (n=73) vs 35.4% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
30% (n=73) vs 36.2% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
13.7% (n=58) vs 25% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
32.3% (n=33) vs 25% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
21.4% (n=30) vs 25% (n=32) Rituximab-EU @ 1wk
NCT01643928 · Phase na · registry result, not featured evidence
35.7% (n=58) vs 54.8% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
46.9% (n=33) vs 54.8% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
46.4% (n=30) vs 54.8% (n=32) Rituximab-EU @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
51.8% (n=58) vs 66.7% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
51.5% (n=33) vs 66.7% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
44.8% (n=30) vs 66.7% (n=32) Rituximab-EU @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
57.1% (n=58) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
36.4% (n=33) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
36.8% (n=30) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
EULAR Moderate 33.3% (n=73) vs 35.1% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
47.9% (n=73) vs 39.4% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
45.6% (n=73) vs 43.8% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
38.8% (n=73) vs 37.5% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
45.5% (n=73) vs 39.4% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
51.7% (n=73) vs 46.2% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
50% (n=73) vs 46.6% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
DAS Low Disease Activity 14.5% (n=73) vs 10.8% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
23.9% (n=73) vs 25.4% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
30.9% (n=73) vs 32.9% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
41.8% (n=73) vs 44.4% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
36.4% (n=73) vs 38% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
35% (n=73) vs 36.9% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
32% (n=73) vs 37.9% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
DAS Remission 8.7% (n=73) vs 4.1% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
16.9% (n=73) vs 8.5% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
26.5% (n=73) vs 20.5% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
28.4% (n=73) vs 29.2% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
25.8% (n=73) vs 25.4% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
25% (n=73) vs 16.9% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
28% (n=73) vs 24.1% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
HAQ-DI -0.2 vs -0.2 Rituximab score @ 3wk
absolute change · score
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
-0.3 vs -0.3 Rituximab score @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-0.4 vs -0.5 Rituximab score @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-0.4 vs -0.6 Rituximab score @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-0.3 vs -0.6 Rituximab score @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-0.4 vs -0.6 Rituximab score @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-0.4 vs -0.5 Rituximab score @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
DAS28-CRP -1.24 vs -1.86 Rituximab-EU score @ 1wk
absolute change · score
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-1.94 vs -1.86 Rituximab-EU score @ 1wk
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
-1.95 vs -1.86 Rituximab-EU score @ 1wk
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.03 vs -2.59 Rituximab-EU score @ 6wk
absolute change · score
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.54 vs -2.59 Rituximab-EU score @ 6wk
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
-2.66 vs -2.59 Rituximab-EU score @ 6wk
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.37 vs -2.78 Rituximab-EU score @ 13wk
absolute change · score
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.66 vs -2.78 Rituximab-EU score @ 13wk
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
-2.76 vs -2.78 Rituximab-EU score @ 13wk
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.35 vs -2.32 Rituximab-EU score @ 25wk
absolute change · score
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.24 vs -2.32 Rituximab-EU score @ 25wk
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
-2.5 vs -2.32 Rituximab-EU score @ 25wk
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence

+ 102 further endpoints in the CSV export.

Rituximab-abbs (Truxima)

DAS28-CRP -3 vs -3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR 6.7 vs 6.7 Rituxan score @ 0wk
absolute change · score
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
-2.5 vs -2.5 Rituxan score @ 24wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.9 vs -2.8 Rituxan score @ 48wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR -3.3 vs -3.3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

Non-Hodgkin Lymphoma

Shared mechanism: CD20 · full Non-Hodgkin Lymphoma pipeline

PF-05280586

Marketed by Pfizer

Approved in Non-Hodgkin Lymphomabiologic (registry-typed, subtype undisclosed)
Reliable signal

NCT02213263 · Phase 3 · completed

The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.

Reported efficacy

Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)

Result source: NCT02213263

Rituximab-abbs (Truxima)

Marketed by Celltrion and partners

Approved in Non-Hodgkin Lymphomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Hodgkin Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Rituximab-abbs (Truxima): no structured comparison results are available for Non-Hodgkin Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PF-05280586
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) NCT02213263 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-05280586's landscape · Rituximab-abbs (Truxima)'s landscape